Pfizer is in talks to acquire cancer drug developer Seagen. According to The Wall Street Journal, citing sources familiar with the matter, while the process is at an early stage and there is no guarantee that the deal will take place.
One of the obstacles to concluding a deal could be antitrust laws, the interlocutors of the publication said. According to them, if it does take place, it will be quite large: Seagen’s market value is about $30 billion, and the company will also receive a bonus in excess of this amount.
Seagen generated nearly $2 billion in sales last year.
The newspaper’s interlocutors specify that Pfizer considered buying this company last year, when Seagen was negotiating its acquisition of pharmaceutical Merck & Co. The cost of a possible deal at that time was about $40 billion. The parties could not reach an agreement: as Bloomberg wrote, the negotiations stalled due to disagreements on the share price.
Source: Rosbalt
Mario Twitchell is an accomplished author and journalist, known for his insightful and thought-provoking writing on a wide range of topics including general and opinion. He currently works as a writer at 247 news agency, where he has established himself as a respected voice in the industry.
